Safety and efficacy of advanced combination therapies for treating inflammatory bowel disease in adults: a systematic review and meta-analysis

1

This systematic review evaluates the safety of advanced combination therapy (ACT) in adults with inflammatory bowel disease (IBD).
2

Fifty-two studies involving 2022 participants were included, focusing on various drug combinations for IBD treatment.
3

Pooled analyses indicated low rates of serious adverse events (SAEs) and treatment discontinuations, but with very low certainty of evidence.
4

The most common drug combinations were anti-TNFa plus integrin inhibitors and IL-23 plus integrin inhibitors.
5

The review highlights the need for larger, well-designed trials to better understand the safety and efficacy of ACT in IBD.

Bmj Open Gastroenterology

by Shellie Radford, Daniel Arruda Navarro Albuquerque, Zara Najeeb, Debangsh Agarwal, Anoop John, Morris Gordon, Vassiliki Sinopoulou, Gordon Moran
June 11, 2026

1